Under 1 Day, any sex, with Preterm Infant or Early-Onset Neonatal Sepsis. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
White Blood Cell Count (WBC) (1)Primary· Completed during the first 30 minutes after birth. This sample is going to be taken from the discarded Placental/umbilical blood cord.
Normal Range approximately 6,000 - 30,000 cell/mm3.
Group
Value
95% CI
Placental/Umbilical Cord Blood Sample
8257
± 2966
White Blood Cell Count (WBC) (1) INFANT BLOODPrimary· Completed during the first 6 hours after birth. This sample is going to be taken directly from the participant.
Normal Range: 6.000 - 30.000 cell/mm3.
Group
Value
95% CI
WBC- INFANT BLOOD
7055
± 12400
I/T Ratio (Immature/Total Immature Neutrophil).I/T Ratio Was Calculated by Dividing Immature White Cell Count Total White Cell CountPrimary· Completed during the first 30 minutes after birth. This sample is going to be taken from the discarded Placental/umbilical blood cord.
Normal Range of I/T ratio: \<0.2.
Group
Value
95% CI
Placental/Umbilical Cord Blood Sample
0.09
± 0.13
I/T Ratio (Immature/Total Immature Neutrophil Ratio) INFANT BLOODPrimary· Completed during the first 12 hours after birth. This sample is going to be taken directly from the participant.
Normal Range: \<0.2
Group
Value
95% CI
I/T Ratio. INFANT BLOOD
0.12
± 0.13
CRP (C-Reactive Protein)(1)Primary· Completed during the first 30 minutes after birth. This sample is going to be taken from the discarded Placental/umbilical blood cord.
Normal Range: \< 10,000 ng/mL
Group
Value
95% CI
Placental/Umbilical Cord Blood Sample
413
± 1229
CRP (C-Reactive Protein)(2) INFANT BLOODPrimary· Completed during the first 6 hours after birth. This sample was taken directly from the participant.
Normal Range: \<10.000ng/mL
Group
Value
95% CI
CRP- INFANT BLOOD
785
± 1846
IL-6 (1)Primary· Completed during the first 30 minutes after birth. This sample is going to be taken from the discarded Placental/umbilical blood cord.
Normal Range: 0-10.2 pg/ml
PUCB
Group
Value
95% CI
Placental/Umbilical Cord Blood Sample
61.45
± 392.7
INFANT BLOOD
Group
Value
95% CI
Placental/Umbilical Cord Blood Sample
45.36
± 182.3
IL-6 (Interleukin-6) INFANTS BLOODPrimary· Completed during the first 6hours after birth. This sample is going to be taken directly from the participant.
Normal Range: \<100 pg/mL
Group
Value
95% CI
IL-6 - INFANT BLOOD
45.36
± 182.3
Procalcitonin PUBCPrimary· Within 30 minutes after delivery
Blood was taken from PUBC after delivery
Group
Value
95% CI
Procalcitonin - PUBC
185.9
± 374
Procalcitonin Level Was Measured in the Blood From Placenta and From the Baby Within 6 Hours After BirthPrimary· Procalcitonin Level was measured in the blood from placenta and in Infant's Blood (within 6 hours)
Procalcitonin levels
Group
Value
95% CI
Procalcitonin - Infant's Blood
131.4
± 411.7
Number of Participants With Negative Blood Culture From Blood Drawn From Placenta and From Baby Within 6 Hours After BirthPrimary· Blood sample drawn from placenta and from baby within 6 hours after birth.
Normal Range: Blood Culture Negative
Group
Value
95% CI
Placental/Umbilical Cord Blood Sample
65
Presepsin- PUBCPrimary· First 30 min after birth
Presepsin level was measured in the blood drawn from placenta and from the baby within 6 hours after birth
Group
Value
95% CI
PRESEPSIN- PUCB
4.6
± 1.6
Sponsor's own description
This study evaluates the utility of placental/umbilical cord blood (PUCB) to perform the baseline workup testing for EONS in Very Low Birth Weight Infants: CBC (Complete Blood Count) with differential, Immature/Total ratio (I/T ratio), and blood culture along with CRP and IL-6 levels. A cohort (63 subjects) of preterm infants will be recruited. All the participants will be evaluated for sepsis using placental/umbilical cord blood (PUCB) and subject blood sample during the first 12 hours of life (after birth).
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
NCT06786039 — Clinical Impact of Non-invasive Neurally Adjusted Ventilatory Assist in Very Preterm Infants
· recruiting
NCT06532695 — Development, ADL, Participation, and Quality of Life in Preterm Infants: Longitudinal Research
· recruiting
NCT07238231 — Taiwan Preterm Infant Database: Analysis and Comparison of Birth Conditions and Exploration of Prognostic Factors
· active not recruiting
NCT03518736 — Does Timing Matter? Supporting Play, Exploration, and Early Developmental Intervention
· NA
· active not recruiting
NCT03373721 — Gut Microbiota of Preterm Infants and Full-term Infants at Early Life
· recruiting
Other The University of Texas Medical Branch, Galveston trials
Trials by the same sponsor.
NCT04095260 — Identification of Neuromusculoskeletal Variables Associated With Injury Risk and Performance in High School Athletes.
· not yet recruiting
NCT06800092 — Sildenafil to Prevent and Reduce Cancer Related Cognitive Impairment
· Phase 2, PHASE3
· not yet recruiting
NCT07337915 — Improving Sleep In Midlife Women
· NA
· recruiting
NCT07203287 — Risk of Acute Complications With Rocuronium vs Cisatracurium in Patients With Chronic Kidney Disease
· Phase 4
· recruiting
NCT07087743 — Virtual Reality-Integrated Propulsion Feedback for Stroke Rehab
· NA
· recruiting
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The University of Texas Medical Branch, Galveston
Last refreshed: 10 August 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03694613.